TheraBionic
Updated: February 18, 2026
Boris Pasche, Co-Founder and CEO
Country: Germany | Funding: $40K (+)
Founded: 2001
Website: https://www.therabionic.com/
TheraBionic manufactures FDA-cleared device TheraBionic P1 for the treatment of advanced hepatocellular carcinoma, with or without metastasis. It emits low-frequency radiofrequency electromagnetic fields that inhibit tumor cell growth without affecting normal cell growth. In clinical trials, TheraBionic's tumor-specific radiofrequency has been shown to be effective in shrinking tumors, blocking the growth of new cancer cells and increasing overall survival. The device is compact and easy to use. In multiple studies, patients treated with the device did not experience the debilitating side effects associated with other cancer treatments. The TheraBionic P1 is also being evaluated for the treatment of metastatic pancreatic cancer in combination with gemcitabine and nab-paclitaxel.
Founded: 2001
Website: https://www.therabionic.com/
TheraBionic manufactures FDA-cleared device TheraBionic P1 for the treatment of advanced hepatocellular carcinoma, with or without metastasis. It emits low-frequency radiofrequency electromagnetic fields that inhibit tumor cell growth without affecting normal cell growth. In clinical trials, TheraBionic's tumor-specific radiofrequency has been shown to be effective in shrinking tumors, blocking the growth of new cancer cells and increasing overall survival. The device is compact and easy to use. In multiple studies, patients treated with the device did not experience the debilitating side effects associated with other cancer treatments. The TheraBionic P1 is also being evaluated for the treatment of metastatic pancreatic cancer in combination with gemcitabine and nab-paclitaxel.
